# NCT05239728 (NCT05239728)

> A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05239728
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Renal Cell
- Interventions: Belzutifan; Pembrolizumab; Placebo
- Enrollment: 1800
- Primary outcome: Disease-Free Survival (DFS)

## Commentary we found

- X threads: 94
- YouTube: 19
- Podcasts: 19
- X videos: 6

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct05239728

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05239728", "email": "<work email>"}; the inbox owner confirms by the emailed link.